We are live on ! Find out more
TENX icon

Tenax Therapeutics
TENX

16 hedge funds and large institutions have $40.6M invested in Tenax Therapeutics in 2015 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $35.9M → $40.6M (+$4.76M)

0% more funds holding

Funds holding: 16 → 16 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.43%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
2
Increased
1
Reduced
1
Closed
2
Calls
$12.2M
Puts
–
Net Calls
+$12.2M
Net Calls Change
+$12.2M

Top Buyers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
+$1.25M
2
Creative Planning
Creative Planning
Kansas
+$114K
3
OM
Opaleye Management
Massachusetts
+$114K

Top Sellers

Rank Fund Capital Flow
1
OPPM
Opus Point Partners Management
New York
-$812K
2
SM
Sabby Management
Florida
-$456K
3
EGA
Eagle Global Advisors
Texas
-$63K
4
RCM
Rotella Capital Management
Washington
-$38K
5
RI
RTW Investments
New York
-$8K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$9.91M -$456K -4 -5%
RCM
2
RA Capital Management
Massachusetts
$9.85M – – –
BC
3
Broadfin Capital
New York
$7.26M – – –
GPP
4
Great Point Partners
Connecticut
$4.09M – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$3.6M – – –
OM
6
Opaleye Management
Massachusetts
$2.34M +$114K +1 +5%
BBA
7
Baker Bros. Advisors
New York
$1.31M +$1.25M +11 New
Deutsche Bank
8
Deutsche Bank
Germany
$534K – – –
Bank of New York Mellon
9
Bank of New York Mellon
New York
$477K – – –
Geode Capital Management
10
Geode Capital Management
Massachusetts
$296K – – –
BFA
11
BlackRock Fund Advisors
California
$241K – – –
Creative Planning
12
Creative Planning
Kansas
$162K +$114K +1 New
Verition Fund Management
13
Verition Fund Management
Connecticut
$145K – – –
BIT
14
BlackRock Institutional Trust
California
$117K – – –
Northern Trust
15
Northern Trust
Illinois
$91K – – –
Goldman Sachs
16
Goldman Sachs
New York
$79K – – –
FNYS
17
First New York Securities
New York
$29.5K – – –
BIM
18
BlackRock Investment Management
Delaware
$13K – – –
Morgan Stanley
19
Morgan Stanley
New York
$13K – – –
FMA
20
FNY Managed Accounts
New York
$11.1K – – –
Citigroup
21
Citigroup
New York
$7K – – –
UBS Group
22
UBS Group
Switzerland
$7K – – –
AIG
23
American International Group
New York
$4.8K – – –
KCM
24
Karp Capital Management
California
$3K – – –
Royal Bank of Canada
25
Royal Bank of Canada
Ontario, Canada
$3K – – –
1
2

TENX Hedge Fund Activity: Q2 2015 in Review

16 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Tenax Therapeutics (TENX) for Q2 2015, worth a combined $40.6M — up 13% from $35.9M a quarter earlier.

Fund positioning in TENX was balanced in Q2 2015: 2 funds opened new positions, 2 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $1.25M. The largest seller was Opus Point Partners Management, exiting entirely with an estimated $812K sold.

  • 16 institutional investors held Tenax Therapeutics (TENX) as of Q2 2015, unchanged from Q1 2015.
  • Funds reported $40.6M of Tenax Therapeutics stock for Q2 2015, up 13% quarter-over-quarter.
  • 2 funds opened new Tenax Therapeutics positions in Q2 2015 and 2 closed out, a net change of 0 holders.
  • The largest Tenax Therapeutics buyer in Q2 2015 was Baker Bros. Advisors, an estimated $1.25M added.
  • The largest Tenax Therapeutics seller in Q2 2015 was Opus Point Partners Management, an estimated $812K sold.

Based on aggregated 13F filings for Q2 2015.